Summary
In a significant market movement during November 2025, Artios was the subject of a vc funding. The transaction achieved a gross valuation of £87,244,458. Leading the round was Novartis Venture Fund, Sofinnova Partners, SV Health Investors, Omega Funds, Pfizer Ventures, Invus, RA Capital Management, M Ventures, Janus Henderson Investors, Avidity Partners, Piper Heartland Healthcare Capital, RA Capital Management, EQT Life Sciences, Andera Partners, Schroders Capital.
This transaction was brokered by an undisclosed advisor. The deal reflects ongoing market confidence within its sector.
Lead Investor / Acquirer
Novartis Venture Fund
Lead Investor / Acquirer
Sofinnova Partners
Lead Investor / Acquirer
SV Health Investors
Lead Investor / Acquirer
Omega Funds
Lead Investor / Acquirer
Pfizer Ventures
Lead Investor / Acquirer
Invus
Lead Investor / Acquirer
RA Capital Management
Lead Investor / Acquirer
M Ventures
Lead Investor / Acquirer
Janus Henderson Investors
Lead Investor / Acquirer
Avidity Partners
Lead Investor / Acquirer
Piper Heartland Healthcare Capital
Lead Investor / Acquirer
RA Capital Management
Lead Investor / Acquirer
EQT Life Sciences
Lead Investor / Acquirer
Andera Partners
Lead Investor / Acquirer
Schroders Capital
Advising Broker
Undisclosed Firm
Related Deals in Healthcare & Biotech
Growth prioritisedOriginal Source
This funding round is sourced from the Tech.eu Funding Explorer. View the full record, investors, and citations there.
View on Tech.eu Funding ExplorerFunding data via Tech.eu Funding Explorer, licensed under CC BY 4.0. See our methodology.
AI Insight Lenses
ProAI-generated analysis from four professional perspectives. Powered by PE Deals.
Sign in to unlock AI Lenses
Sign in